Key result
IV autologous mesenchymal stem cells reduce infarct size by ~13 percentage points after MI.
Absolute Event Rate: 19% vs 32%
p-value: p=0.01
Systemic delivery of bone marrow-derived mesenchymal stem cells (MSCs) is a noninvasive approach for myocardial repair. We aimed to test this strategy in a pig model of myocardial infarction. Pigs (n = 8) received autologous MSCs (1 x 10(6)/kg body weight) labeled with fluorescent dye 48 h post proximal left anterior descending artery (LAD) occlusion. Hemodyamics, infarct size, and myocardial function were assessed at baseline and after 1 month. Morphologic analysis revealed that labeled MSCs migrated in the peri-infarct region, resulting in smaller infarct size (32 +/- 7 vs. 19 +/- 7%, p = 0.01), higher fractional area shortening (23 +/- 3 vs. 34.0 +/- 7%, p = 0.001), lower left ventricular end diastolic pressure (18.7 +/- 5 vs. 10.2 +/- 4 mmHg, p = 0.02) and higher +dp/dt (4,570 +/- 540 vs. 6,742 +/- 700 mmHg/s, p = 0.03) during inotropic stimulation. Systemic intravenous delivery of MSCs to pigs limits myocardial infarct size and is an attractive approach for tissue repair.
No takes yet. Share an insight, caveat, or question.
Krause et al. (2007) studied Myocardial infarction (n=8). Autologous mesenchymal stem cells (MSCs) vs. Control was evaluated on Infarct size (p=0.01). Systemic intravenous delivery of autologous mesenchymal stem cells limited infarct size (19% vs 32%, p=0.01) and improved fractional area shortening (34% vs 23%, p=0.001) in a pig model of MI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: